Exendin-(9,39) is a competitive antagonist of Glucagon-Like Peptide-1 (GLP-1) at its receptor. However, it is unclear if it has direct and unique effects of its own. We tested the hypothesis that Exendin-(9,39) and GLP-1-(9,36) amide have direct effects on hormone secretion and β-cell function as well as glucose metabolism in healthy subjects. Glucose containing [3-3H]-glucose was infused to mimic the systemic appearance of glucose after a meal. Saline (S), GLP-1-(9,36) amide (G), or Exendin-(9,39) at 30pmol/kg/min (Ex30) or 300pmol/kg/min (Ex300) were infused in random order on separate days. Integrated glucose concentrations were slightly but significantly increased by Exendin-(9,39) (365±43 vs. 383±35 vs. 492±49 vs. 337±50 mmol per 6hr, S, Ex30, Ex300 and G respectively, p=0.05). Insulin secretion did not differ amongst groups. However, insulin action was lowered by Exendin-(9,39) (25±4 vs. 20±4 vs. 18±3 vs. 21±4 10-4 dl/kg(min per μU/ml), p=0.02), resulting in a lower disposition index during Exendin-(9,39) infusion (1118±118 vs. 816±83 vs. 725±127 vs. 955±166 10-14 dl/kg/min2 per pmol/l, p=0.003). Endogenous glucose production and glucose disappearance did not differ significantly amongst groups. We conclude that Exendin-(9,39), but not GLP-1-(9,36) amide, decreases insulin action and disposition index in healthy humans.

Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, β-Cell Function and Glucose Metabolism in Non-Diabetic Subjects.

PICCININI, FRANCESCA;DALLA MAN, CHIARA;COBELLI, CLAUDIO;
2013

Abstract

Exendin-(9,39) is a competitive antagonist of Glucagon-Like Peptide-1 (GLP-1) at its receptor. However, it is unclear if it has direct and unique effects of its own. We tested the hypothesis that Exendin-(9,39) and GLP-1-(9,36) amide have direct effects on hormone secretion and β-cell function as well as glucose metabolism in healthy subjects. Glucose containing [3-3H]-glucose was infused to mimic the systemic appearance of glucose after a meal. Saline (S), GLP-1-(9,36) amide (G), or Exendin-(9,39) at 30pmol/kg/min (Ex30) or 300pmol/kg/min (Ex300) were infused in random order on separate days. Integrated glucose concentrations were slightly but significantly increased by Exendin-(9,39) (365±43 vs. 383±35 vs. 492±49 vs. 337±50 mmol per 6hr, S, Ex30, Ex300 and G respectively, p=0.05). Insulin secretion did not differ amongst groups. However, insulin action was lowered by Exendin-(9,39) (25±4 vs. 20±4 vs. 18±3 vs. 21±4 10-4 dl/kg(min per μU/ml), p=0.02), resulting in a lower disposition index during Exendin-(9,39) infusion (1118±118 vs. 816±83 vs. 725±127 vs. 955±166 10-14 dl/kg/min2 per pmol/l, p=0.003). Endogenous glucose production and glucose disappearance did not differ significantly amongst groups. We conclude that Exendin-(9,39), but not GLP-1-(9,36) amide, decreases insulin action and disposition index in healthy humans.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11577/2574121
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact